École d’été

SSM11 Summer School in Medicines

SSM11 offers a unique 50-hour training program on drug discovery, development and market access under a multicultural sponsorship in the wonderful setting of Montreal, Quebec. Make plans now for one full week of lively presentations and direct interactions with the Faculty, including Case Studies and Workshops with Industry, covering the whole value chain of medicines, from “idea to market”. SSM11 Faculty members are leaders in their field and contribute to create one of the most innovative and focused programs in drug discovery & development currently offered.

Program

Opening Note

Dear participants to SSM11,

On behalf of the Université de Montréal, it’s a real pleasure for me to welcome you at this 11th edition of the Summer School of medicines. We’re honoured to organize this summer school in collaboration with three of our privileged international academic partners, the University of Barcelona and Université Paul Sabatier in Toulouse and University of Sao Paolo (Brazil).

For several years now, this summer school has represented an important international outreach for us in our mission to train the next generation of scientists in the biopharmaceutical sector. U de Montreal is the 2th largest research U in Canada, with more than 62 thousands students attending, and over 400M Euro in research funding each year. In North America, the region of Montreal is ranked 10th among the major hubs of Biopharmaceutical research. Of the sixinnovative medicines ever developed in Canada and approved by the American FDA, four were developed in the region of Montreal.

Drug discovery is serious business. It has impact on economics, politics, ethics and most importantly on people. Patients who suffer from diseases we don’t yet fully understand. As you will appreciate this week, developing new drugs that are safe and effective is one of the most difficult challenges facing mankind. It involves science, lots of it, in so many different fields that nobody can do it alone in his or her lab. We need specialists that can see the big picture and understand the language of other specialists, their challenges and opportunities, from idea to market.

This is why we are here. To give you the larger picture. Because it is an international school, with faculty and students coming from several countries in the European Union and North America, SSM11 is also an opportunity to make contacts and build your network. Do not hesitate to ask questions either after talks or during the general discussions that will follow at the end each day. Several speakers will stay with us after their talk so see this as an opportunity to meet and discuss with them.

We wish you all the best learning experience possible with SSM11.

Denis deBlois
Chairman, SSM11
For the Scientific and Organizing Committee

SSM11– UNIVERSITE DE MONTREAL – JUNE 8-15, 2019

Program

SATURDAY, June 8, 2019

Pavilion Jean-Coutu, room S1-151 & Agora

15:00 – 16:00 Registration
16:00 
– 16:15 OFFICIAL OPENING – 11th Summer School on Medicines (SSM11)

Organizing committee

16:15 – 17:00 Keynote Opening Lecture 1 (KNL1) : New models of translational research from academia to industry

Michel Bouvier, Director of Institute for resesarch in immunology and cancer (IRIC), Montréal

17:00 – 17:45 Keynote Opening Lecture 2 (KNL2): Recent advances in G protein-coupled receptors as therapeutic targets

Jean-Philippe Pin, Director of Functional Genomic Institute (IGF), Montpellier, France

17:45 – 20:00 Poster Session and Welcome Reception at Pavilion Jean-Coutu

SUNDAY, June 9, 2019

Pavilion Jean-Coutu, room S1-151 & Agora

SESSION I : DRUG R&D, AN OVERVIEW FROM TARGET TO MARKET

Chairperson: Jordi Quintana

9:00 – 10:15 (L1) Overview of drug discovery

Denis deBlois UdeM

10:15 – 10:45 Health break
10:45 
– 12:00 (L2) Overview of clinical development

Dan Chiche, Chief Medical Officer, Neomed Institute, Montreal

12:00 – 13:00 Lunch
13:00 
– 14:00 (L3) Molecules and money: Overview of business development

Steven Klein, VP Business Development, IRIC-Commercialization of Research (IRICoR), Montreal

14:00 – 15:00 (L4) Novel, non obvious, useful? Intellectual property as a discovery engine

Steven Lam, Partner and Patent Agent at ROBIC, S.E.N.C.R.L. / LLP

15:00 – 15:15 Health break

15:15 – 15:45 Plenary discussion with speakers

15:45 – 17:30 Participant Mini-Symposium : Oral and poster presentations

MONDAY, June 10, 2019

Pavilion Jean-Coutu, room S1-151 & Agora

SESSION II : DRUG DISCOVER

Chairperson (AM): Pierre Cordelier

Chairperson (AM): Pierre Cordelier

8:45 – 9:30 (L5) Targeting TNF-alpha to overcome resistance to immunotherapy in melanoma

Bruno Ségui, Centre de recherches en cancérologie de Toulouse

9:30 – 10:15 (L6) Drug discovery – Small molecule

Rodolfo Lavilla, U de Barcelona – Institute of Biomedicine (IBUB)

10:15 – 10:30 Health break
10:30 
– 11:15 (L7) Chemical biology

Jordi Quintana, U Pompeu Fabra, Barcelona

11:15 – 12:00 (L8) Beyond the pill: Systems Pharmacology in Drug Discovery

Rafael Najmanovich, UdeM

12:00 – 13:00 Lunch
Chairperson (PM): Marçal Pastor-Anglada

13:00 – 13:45 (L9) Biological drugs : development and manufacturing challenges

Yves Durocher, National Research Council of Canada

13:45 – 14:30 (L10) Oncolytic virus for cancer therapy: from cellular determinants to mathematical modeling of infection

P Cordelier, INSERM, Toulouse

14:30 – 14:45 Health break

14:45 – 15:30 (L11) Beyond the pill: Anti-inflammatory dendrimers call into question pharmaceutical dogmas

Remy Poupot, U Paul Sabatier, Toulouse

15:30 – 16:00 Plenary discussion with speakers
16:00 – 17:00 Visit of IRIC Drug Discovery Platforms (HTS– Medicinal chemistry – Histology– Cytometry )

TUESDAY, JUNE 11, 2019

Pavilion Jean-Coutu, room S1-151

SESSION III : NONCLINICAL DEVELOPMENT

Chairperson: Rémy Poupot

8:45 – 9:30 (L12) Drug-like properties for optimal drug delivery

Grégoire Leclair, UdeM

9:30 – 10:15 (L13) Membrane proteins in drug-transporter interactions

Marçal Pastor-Anglada, U de Barcelona – Institute of Biomedicine (IBUB)

10:15 – 10:30 Health break
10:30 
– 11:15 (L14) Toxicology / Non clinical safety evaluation

Violetta Dimitriadou, VP Scientific Operations, IRICoR, Montreal

11:15 – 12:00 (L15) Beyond the Pill – Modeling and simulation to optimize PK / PD relationship

Fahima Nekka, UdeM

12:00 – 13:00 Lunch

  • SESSION IV : CASE STUDY – INTELLECTUAL PROPERTY AND TECHNOLOGY WATCH

13:00 – 13:30 Case presentation and outline of challenges

Remy Poupot, U Paul Sabatier, Toulouse

13:30 – 16:00 Group session (students work in small teams) – Health break at convenience 16:00 – 17:00 Each team reports / General discussion

WEDNESDAY, JUNE 12, 2019

Pavilion Jean-Coutu, room S1-111

SESSION VI: CLINICAL DEVELOPMENT & POST-MARKETING FOLLOW-UP

Chairperson: Denis deBlois

8:30 – 9:20 (L16) Learning studies : First-in-Man (Phase I)

Marc Lefebvre, Cofounder of Algorithme Pharma – An Altasciences Company

9:20 – 10:10 (L17) Learning studies : Proof of concept studies (Phase II)

Marc Riviere, General Partner & CMO, TVM Life Science Management Inc

10:10 – 10:40 Health break
10:40 
– 11:30 (L18) Confirmatory studies (Phase III) : the perspective of the regulatory agency

Ariel E. Arias, Senior Advisor, Centre for Biologics Evaluation, Biologics and Genetic Therapies Directorate, Health Canada

11:30 – 12:00 12:00 – 13:15 13:15 – 14:15

Plenary discussion with speakers

Lunch
(L19) Safety in the Real-World : Pharmacovigilance and Therapeutic Risk Management

Yola Moride, UdeM

SESSION VII : CASE STUDY II – REGULATORY STRATEGIES

14:15 – 14:45 Case presentation and outline of challenges

Patrick Colin, PCC Inc

14:45 – 15:00 15:00 – 16:00 16:15 – 17:00

Health break
Group session (students work in small teams) Each team reports / General discussion

THURSDAY, JUNE 13, 2019

Pavilion Jean-Coutu, room S1-111

8:45 – 9:30 (L20) Working with the FDA and other government agencies on clinical trials

Mark Kester, Director, Nanostar Institute, Virginia USA

SESSION VIII : CASE STUDY III – STAKEHOLDERS’ PERSPECTIVES (Part 1)

9:30 – 10:00 Case presentation and outline of challenges

Denis deBlois UdeM

10:00 – 11:00 Group session (students work in small teams) 11:00 – 11:15 Health break

SESSION IX: MARKET ACCESS

11:15 – 12:00 (L21) Pharmaco-economics 101

Alice Dragomir, McGill U

12:00 – 13:00 Lunch
13:00 
– 13:45 L(22) Third payer perspective : Health technology assessment

Sylvie Bouchard, Director of drug evaluation, INNESS

13:45 – 14:30 (L23) Market access – Industry perspective

Frédéric Lavoie, VP Access and Government Relations, Pfizer Canada

14:30 – 15:00 15:00 – 15:30 15:30 – 16:15

Plenary discussion with speakers Health break

(L24) Start-up Creation, From the Bench to the Bedside, the journey of a faculty entrepreneur

Mark Kester, Director, Nanostar Institute, Virginia USA

CASE STUDY – STAKEHOLDERS’ PERSPECTIVES (Part 2)

16:15 – 17:15 Each team reports / General discussion

FRIDAY, JUNE 14, 2019

Pavilion Jean-Coutu, room S1-151 & Agora

INDUSTRIAL SYMPOSIUM – DEEP LEARNING IN CURRENT BIOPHARMACEUTICAL DRUG DEVELOPMENT

Chairperson: Jean-Pierre Moreau, Recherche Continuum, Montreal

9:00 Opening Remarks – Jean-Pierre Moreau, Recherche Continuum
9:15 Metatox: Meta Learning for Assessing Toxicity-Related Drug Safety

Therence Bois, InVivoAI, Montréal

Break
10:15 Introduction of SSM11 keynote speaker 
– Denis deBlois, Chairman SSM11 10:20 Ceramide Nanoliposomes: A Case Study

Mark Kester, Director, Nanostar Institute, Virginia USA

11:20 Prediction of Clinical QTc Changes Based Upon Preclinical Ion Channel Data

William Crumb, Nova Research Labs, New Orleans

11:50-13:30 Lunch break (not offered on site)
13:30 Proof of Concept Comprehensive Ex-vivo Neurological Assay

Lois Miraucourt, CiToxLAB, Laval

14:05 Neomed/CDRD Join Resources for New Pan-canadian Support to Drug Discovery

Youssef Bennani, adMare BioInnovations, Montréal

Break

14:40 Preclinical & Clinical development of Etripamil for Paroxysmal Systolic Ventricular Tachycardia (PSVT)

Philippe Douville, Milestone Pharmaceuticals, Montréal

15:10 Introduction of SSM11 keynote speaker – Denis deBlois, Chairman SSM11
15:15 Preclinical and Clinical Development of Palovarotene for Ultra-rare Bone Diseases

Michael Harvey, VP Drug Development, Clementia Pharma – An Ipsen Company, Montreal

16:05 Networking cocktail

SATURDAY, JUNE 15, 2019

Pavilion Jean-Coutu, room S1-111

9:00 – 10:00 (L25) Beyond the Pill – AI meets drug R&D

Steven Sanche, Los Alamos National Laboratory, USA

SESSION X : START-UP CREATION, INVESTMENT & BUSINESS DEVELOPMENT

Chairperson: Steven Klein, VP Business development, IRICoR

10:00 – 10:15 Health break
10:15 
– 11:00 (L26) Translational research – Stem cell expansion strategy for cancer treatment

Anne Marinier, Institute for resesarch in immunology and cancer (IRIC), Montréal

11:00 – 11:45 (L27) Public-Private Partnerships for Drug Discovery and Development

Steven Xanthoudakis, Chief Business Development Officer at Consortium Québécois en développement du médicament (CQDM)

11:45 – 12:00 Plenary discussion 12:00 – 13:00 Lunch

SESSION XI: CARING ABOUT CAREERS: NAVIGATING THE ECOSYSTEM OF BIOPHARMA

13:00 – 13:45 (L28) Career development in the biopharmaceutical sector

Michelle Savoie, Université de Montréal, Québec

13:45 – 14:00 Plenary discussion with SSM11 faculty
14:00 – 14:15 SSM11 Wrap-up, Closing comments and Overture towards SSM12

Site web SSM11 : https://summerschoolonmedicines7.wordpress.com/

Ce contenu a été mis à jour le 24 octobre 2022 à 20:32.